{"id":"NCT00257660","sponsor":"Ipsen","briefTitle":"Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia","officialTitle":"A Phase III Multicentre, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Dysport® for the Treatment of Cervical Dystonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-10-10","primaryCompletion":"2006-09","completion":"2006-09","firstPosted":"2005-11-23","resultsPosted":"2010-05-10","lastUpdate":"2022-09-28"},"enrollment":116,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cervical Dystonia"],"interventions":[{"type":"BIOLOGICAL","name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this study is to demonstrate the effectiveness and safety of 500 units of Dysport manufactured at a new manufacturing facility in Europe.","primaryOutcome":{"measure":"Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)","timeFrame":"Baseline and Week 4","effectByArm":[{"arm":"Dysport 500 Units","deltaMin":-13.99,"sd":12.33},{"arm":"Placebo","deltaMin":-5.23,"sd":9.33}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":22,"countries":["United States","Russia"]},"refs":{"pmids":["20359934","25324317"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":55},"commonTop":["Neck pain","Dysphagia","Injection site pain"]}}